PCM
RPTX

Penserra Capital Management’s Repare Therapeutics RPTX Stock Holding History

Penserra Capital Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-850
Closed -$22K – 1523
2021
Q3 		$22K Buy
850
+10
+1% +$323 ﹤0.01% 1229
2021
Q2 		$26K Buy
840
+10
+1% +$327 ﹤0.01% 1111
2021
Q1 		$25K Sell
830
-15
-2% -$510 ﹤0.01% 932
2020
Q4 		$28K Buy
+845
New +$25.2K ﹤0.01% 802

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Penserra Capital Management's RPTX Position: Q4 2021 in Review

Penserra Capital Management sold out of Repare Therapeutics (RPTX) in Q4 2021, closing a stake of 850 shares — an estimated $22K sold.

Penserra Capital Management first reported a position in RPTX in Q4 2020 and held it in 4 quarters. The position peaked at $28K in Q4 2020. 67 funds tracked by Wall St. Rank hold RPTX as of Q4 2021.

  • Penserra Capital Management reported no remaining Repare Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 850 Repare Therapeutics shares in Q4 2021, an estimated $22K.
  • Penserra Capital Management first reported a position in Repare Therapeutics in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Repare Therapeutics position peaked at $28K in Q4 2020.
  • 67 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.